Sanofi CEO Paul Hud­son of­floads two port­fo­lios to Ger­man phar­ma com­pa­ny in con­tin­ued ef­fort to prune prod­ucts

Sanofi warned ear­li­er this year that some se­ri­ous cuts were in or­der. CEO Paul Hud­son made good on that promise this week, prun­ing more than a dozen mar­ket­ed prod­ucts.

Ger­many-based Neu­rax­pharm re­vealed yes­ter­day that it struck a deal for Sanofi’s CNS and pain and vas­cu­lar dis­ease port­fo­lios. While the com­pa­nies are keep­ing the fi­nan­cial terms un­der wraps for now, Neu­rax­pharm did say it’s swal­low­ing 17 prod­ucts rep­re­sent­ing 38 brands, in­clud­ing neu­rolep­tics Noz­i­nan and Tiapri­dal, anx­i­ety med Tranx­ene and an­tipsy­chotics Dog­matil and Largac­til.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER